Canaccord reiterates Buy ratings on Exact Sciences (EXAS) and Guardant Health (GH) after Freenome announced top-line results from its prospective PREEMPT colorectal cancer study, which was designed to validate the first version of the company’s blood-based CRC screening test. The firm says Freenome’s colorectal cancer and advanced adenoma sensitivities were materially below and near the low end of its base case expectations. The company’s “underwhelming data” provided for blood-based tests thus far could prevent this type of screening from obtaining significant share of the colorectal cancer screening market in the near term, the analyst tells investors in a research note. The firm views the shares of Exact Sciences and Guardant Health as attractive at current levels.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences’ Oncoguard Esophagus test shows efficacy in published study
- 5 Best Healthcare Stocks to Buy in March 2024, According to Analysts
- EXACT Sciences call volume above normal and directionally bullish
- Exact Sciences added to ‘Tactical Outperform’ list at Evercore ISI
- Exact Sciences says Cologuard Plus test results published in NEJM